Vertex Receives the EMA’s CHMP Positive Opinion of Kaftrio (ivacaftor/tezacaftor/elexacaftor) + Ivacaftor Aged 6 Through 11Years with Cystic Fibrosis
Shots:
- The EMA’s CHMP adopted a positive opinion for the label extension of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for CF in patients aged 6-11yrs. who have 1 F508del mutation in CFTR gene
- If Kaftrio + ivacaftor is approved, it will provide a new treatment option to physicians for young patients to help combat this life-shortening condition shortly
- Kaftrio + ivacaftor was approved in the EU for CF in patients aged ≥12yrs. who have at least one copy of the F508del mutation in the CFTR gene. Kaftrio showed unprecedented clinical benefit for eligible with CF
Ref: Vertex | Image: Vertex
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
